Skip to content

News

OCRFA Funded Study Explores Implant that Detects Ovarian Ca...

OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued

Vaccine for Ovarian Cancer Shows Promising Results in Pilot...

Vaccine for Ovarian Cancer Shows Promising Results in Pilot Trial

(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer. In this pilot trial, 25 patients with advanced epithelial recurrent ovarian cancer were either given the vaccine alone, with the chemotherapy drug bevacizumab, or a … Continued

FDA Approves Rucaparib as Maintenance Treatment for Platinu...

FDA Approves Rucaparib as Maintenance Treatment for Platinum Sensitive Recurrent Ovarian Cancer

(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy. The evidence that led to the FDA approving rucaparib comes from the phase 3 ARIEL3 clinical trial, which enrolled 564 … Continued

Updates from 2018 Annual Meeting on Women’s Cancer

Updates from 2018 Annual Meeting on Women’s Cancer

(April 4, 2018) It’s an exciting time for ovarian cancer research! Ovarian cancer clinicians, researchers and advocates came together in New Orleans at the end of March for the Annual Meeting on Women’s Cancer, hosted by the Society of Gynecologic Oncology (SGO). Meeting attendees learned about the latest developments in ovarian cancer research, treatment, and … Continued

Genetic Counseling and Testing by Oncologists Feasible for ...

Genetic Counseling and Testing by Oncologists Feasible for Ovarian Cancer Patients

(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations. Due to the limited number of genetic counselors and the increase in demand for BRCA mutation testing, ovarian cancer patients don’t always have the ability or opportunity to … Continued

Discovery of New Gene Mutation That Increases Ovarian Cance...

Discovery of New Gene Mutation That Increases Ovarian Cancer Risk, Passed Down Through Paternal Lineage

(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a mutation of an unidentified gene that increases both the risk of early onset ovarian cancer and prostate cancer. Using the Familial Ovarian Cancer Registry at … Continued

US Preventive Services Task Force: Ovarian Cancer Screening...

US Preventive Services Task Force: Ovarian Cancer Screening Not Effective for Low-Risk Women

(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not effective in reducing mortality from the disease. Furthermore, they stated that screening for ovarian cancer carries certain risk and harms that may be substantial, and … Continued

Ovarian Cancer Risk and BRCA1 Methylation

Ovarian Cancer Risk and BRCA1 Methylation

(January 31, 2018) A study published in the Annals of Internal Medicine explains that researchers now believe that the methylation of normal BRCA1 gene promotion, not solely BRCA1 mutation, is a risk factor for ovarian cancer. Methylation can be detrimental because it blocks a gene from being transcribed, which means that it can’t repair any … Continued

HIPEC Beneficial in Late Stage Ovarian Cancer

HIPEC Beneficial in Late Stage Ovarian Cancer

(January 29, 2018) A study recently published in the New England Journal of Medicine looked at the difference between two treatment strategies for newly diagnosed stage III epithelial ovarian cancer patients, with the goal of identifying the treatment with a higher rate of recurrence free survival. The first treatment option, typical for advanced stage ovarian … Continued

Can Cancer Be Detected and Located by a Blood Test?

Can Cancer Be Detected and Located by a Blood Test?

(January 25, 2018) CancerSEEK is a blood test designed to detect cancer by analyzing levels of proteins and mutations in cell-free DNA. The goal of this particular blood test is to assist in early detection, and therefore decrease cancer related deaths, for ovarian, liver, stomach, pancreas, esophagus, colorectum, lung, and/or breast cancers. The results of … Continued

OCRFA Awards $5.3 Million in Scientific Research Grants for...

OCRFA Awards $5.3 Million in Scientific Research Grants for 2018

(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million. This year’s grants have been awarded to twenty top scientists at sixteen leading medical centers across the country. “Our 2018 grantees are truly some of … Continued

OCRFA Research Shows Novel Combination Therapy Effective in...

OCRFA Research Shows Novel Combination Therapy Effective in Ovarian Cancer

(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.